Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

With the advent of novel agents, the demand for docetaxel in CRPC patients might ... not have been long enough to determine the actual OS. Second, this study was a retrospective study using ...

Biotech’s TROP2 antibody drug conjugate sac-TMT for marketing in second indication: Chengdu, China Wednesday, March 12, 2025, 11:00 Hrs [IST] Sichuan K ...

AstraZeneca has reported positive “high-level” outcomes from the randomised Phase III MATTERHORN trial of Imfinzi (durvalumab ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as ...

During the study period, 79 CRPC patients received docetaxel-based chemotherapy at ... died of another cause. The median OS was 22.5 months, and the 1-year OS rate was 78.8 %.

Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...

MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard ...

A strong trend in overall survival benefit was observed, with final OS analysis pending ... oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically ...

Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

Detailed price information for Revolution Medicines Inc (RVMD-Q) from The Globe and Mail including charting and trades.